EDG4 (LPAR2) Human shRNA Plasmid Kit (Locus ID 9170)
CAT#: TG313298
LPAR2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 3 publications. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (2)
Specifications
Product Data | |
Product Name | EDG4 (LPAR2) Human shRNA Plasmid Kit (Locus ID 9170) |
Locus ID | 9170 |
UniProt ID | Q9HBW0 |
Synonyms | EDG-4; EDG4; LPA-2; LPA2 |
Vector | pGFP-V-RS |
Format | Retroviral plasmids |
Kit Components | LPAR2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 9170). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
RefSeq | NM_004720, NM_004720.1, NM_004720.2, NM_004720.3, NM_004720.4, BC025695, BC025695.1, BM840024, NM_004720.6 |
Summary | This gene encodes a member of family I of the G protein-coupled receptors, as well as the EDG family of proteins. This protein functions as a lysophosphatidic acid (LPA) receptor and contributes to Ca2+ mobilization, a critical cellular response to LPA in cells, through association with Gi and Gq proteins. An alternative splice variant has been described but its full length sequence has not been determined. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (3)
The use of this RNAi has been cited in the following citations: |
---|
Roles of endothelial cells in the regulation of cell motility via lysophosphatidic acid receptor-2 (LPA2) and LPA3 in osteosarcoma cells
,Minami, K;Ueda, N;Ishimoto, K;Kurisu, R;Takamoto, M;Ikeda, H;Tsujiuchi, T;,
Experimental and molecular pathology
,PubMed ID 33347862
[LPAR2]
|
Different effects of lysophosphatidic acid receptor-2 (LPA2) and LPA5 on the regulation of chemoresistance in colon cancer cells
,Ishimoto, K;Minami, A;Minami, K;Ueda, N;Tsujiuchi, T;,
J. Recept. Signal Transduct. Res.
,PubMed ID 32672083
[LPAR2]
|
Lysophosphatidic acid receptor-2 (LPA2)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs
,Minami, K;Ueda, N;Ishimoto, K;Tsujiuchi, T;,
Mol. Cell. Biochem.
,PubMed ID 32301060
[LPAR2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...